| Identification | Back Directory | [Name]
H-LEU-SER-LYS-LEU-OH | [CAS]
162559-45-7 | [Synonyms]
LEU-SER-LYS-LEU
H-LEU-SER-LYS-LEU-OH
L-Leucyl-L-seryl-L-lysyl-L-leucine
L-Leucine, L-leucyl-L-seryl-L-lysyl- | [Molecular Formula]
C21H41N5O6 | [MDL Number]
MFCD03093461 | [MOL File]
162559-45-7.mol | [Molecular Weight]
459.58 |
| Hazard Information | Back Directory | [Uses]
H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK.html" class="link-product" target="_blank">KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis[1]. | [in vivo]
H-Leu-Ser-Lys-Leu-OH (LSKL) (100 μg/0.5 mL; i.p.; daily for 4 weeks, accompanied with DMN) protects dimethylnitrosamine (DMN)-treated (10 mg/kg; i.p.; 3 consecutive days a week for 4 weeks) rats from liver atrophy. H-Leu-Ser-Lys-Leu-OH also prevents the progression of hepatic damage and fibrosis[1].
| [References]
[1] Kondou H, et al. A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo. J Hepatol. 2003 Nov;39(5):742-8. DOI:10.1016/s0168-8278(03)00377-5 |
|
|